US CAR T Market Update 2025: Situation, Landscape, and Outlook

  • headshot
    Jeff Liepman Co-founder and Managing Partner
  • headshot
    Ben Maimon, PhD Principal
  • headshot
    Greg Siefkas Associate Principal

Seven years on from the approval of the first CAR T therapy, the market dynamics surrounding the technology continue to change. This paper explores the continued CAR T market evolution in the areas of new reimbursement approaches, target expansion, and the rise of allogeneic T-cell immunotherapies.

Download the White Paper

"*" indicates required fields

*Required field
This field is for validation purposes and should be left unchanged.